Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 30/5/2020
SIETES contiene 93014 citas

 
 
 1 a 20 de 28 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Corbella J. La primera vacuna de la Covid ensayada en personas muestra eficacia. La Vanguardia 2020:19 de mayo. [Ref.ID 103619]
2. Cita con resumen
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young J, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017:1. [Ref.ID 101908]
3.Tiene citas relacionadas Cita con resumen
Anónimo. Concerns about antibiotic cloud prospects for approval. DIA Daily 2016:1. [Ref.ID 100875]
4. Cita con resumen
Anónimo. FDA approves Nucala to treat severe asthma. U.S. Food and Drug Administration 2015:4 de noviembre. [Ref.ID 99610]
5. Cita con resumen
Young K. FDA advisers recommend first-in-class cholesterol-lowering meds. Journal Watch 2015:11 de junio. [Ref.ID 99172]
6. Cita con resumen
Anónimo. FDA approves first biosimilar product Zarxio. U.S. Food and Drug Administration 2015:6 de marzo. [Ref.ID 98838]
7. Cita con resumen
Anónimo. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. U.S. Food and Drug Administration 2014:1. [Ref.ID 98380]
8. Cita con resumen
Stokley S, Jeyarajah J, Yankey D, Yankey D, Gee J, Roark J, Curtis CR, Markowitz L. Human Papillomavirus Vaccination Coverage among Adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014 — United States. Morbidity and Mortality Weekly Report 2014;63:620-4. [Ref.ID 97744]
9. Cita con resumen
Herman AO. Experimental HPV vaccine adds protection against 5 more cancer-causing strains. Journal Watch 2013:4 de noviembre. [Ref.ID 96275]
10. Cita con resumen
Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. Journal of Crohn's and Colitis 2013;7:257-62. [Ref.ID 96072]
11. Cita con resumen
Anónimo. FDA approves antisense therapy for HoFH. DIA Daily 2013:31 de enero. [Ref.ID 94643]
12. Cita con resumen
Jackson LA, Peterson D, Nelson JC, Marcy SM, Naleway AL, Nordin JD, Donahue JG, Hambidge SJ, Balsbaugh C, Baxter R, Marsh T, Madziwa L, Weintraub E. Vaccination site and risk of local reactions in children 1 through 6 years of age. Pediatrics 2013;131:283-9. [Ref.ID 94627]
13.Tiene citas relacionadas
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DAS, for the CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39. [Ref.ID 94117]
14.Tiene citas relacionadas
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS, for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1818-29. [Ref.ID 94116]
15.Tiene citas relacionadas
Sprenger T, Kappos L. Alemtuzumab for multiple sclerosis: who and when to treat?. Lancet 2012;380:1795-7. [Ref.ID 94115]
16.Tiene citas relacionadas Cita con resumen
Anónimo. Alemtuzumab for multiple sclerosis. Lancet 2012;380:1792. [Ref.ID 94114]
17.Tiene citas relacionadas Cita con resumen
Carvajal A, García-Ortega P, Sáinz M, Velasco V, Salado I, Martín Arias LH, Eiros JM, Pérez Rubio A, Castrodeza J. Adverse events associated with pandemic influenza vaccines: Comparison of the results of a follow-up study with those coming from spontaneous reporting. Vaccine 2011;29:519-22. [Ref.ID 89853]
18. Cita con resumen
Anónimo. Reacciones adversas asociadas a las vacunas pandémicas frente a la gripe A (H1N1). Boletín de la Tarjeta Amarilla. Centro Regional de Farmacovigilancia de Castilla y León 2010;29:2-4. [Ref.ID 88865]
19.Tiene citas relacionadas Cita con resumen
Liang X-F, Wang HQ, Wang JZ, Fang H-H, Wu J, Zhu FC, Li R-C, Xia SL, Zhao YL, Li F-J, Yan SH, Yin WD, An K, Feng D-J, Cui X-L, Qi FC, Ju C-J, Zhang YH, Guo ZJ, Chen P-Y, Chen Z, Yan KM, Wang Y. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010;375:56-66. [Ref.ID 87534]
20.Tiene citas relacionadas Cita con resumen
Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché M-K, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010;375:41-8. [Ref.ID 87532]
Seleccionar todas
 
 1 a 20 de 28 siguiente >>